Literature DB >> 26299227

Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Jacob P Kelly1, Robert J Mentz2, Vic Hasselblad2, Justin A Ezekowitz3, Paul W Armstrong3, Faiez Zannad4, G Michael Felker2, Robert M Califf5, Christopher M O'Connor2, Adrian F Hernandez2.   

Abstract

BACKGROUND: Despite initial in-hospital treatment of acute heart failure (HF), some patients experience worsening HF (WHF). There are limited data about the outcomes and characteristics of patients who experience in-hospital WHF. METHODS AND
RESULTS: We assessed the characteristics and outcomes of patients with and without WHF in the ASCEND-HF trial. Worsening HF was defined as at least 1 symptom or sign of new, persistent, or WHF requiring additional intravenous inotropic/vasodilator or mechanical therapy during index hospitalization. We assessed the relationship between WHF and 30-day mortality, 30-day mortality or HF hospitalization, and 180-day mortality. We also assessed whether there was a differential association between early (days 1-3) vs late (day ≥4) WHF and outcomes. Of 7,141 patients with acute HF, 354 (5%) experienced WHF. Patients with WHF were more often male and had a history of atrial fibrillation or diabetes, lower blood pressure, and higher creatinine. After risk adjustment, WHF was associated with increased 30-day mortality (odds ratio 13.37, 95% CI 9.85-18.14), 30-day mortality or HF rehospitalization (odds ratio 6.78, 95% CI 5.25-8.76), and 180-day mortality (hazard ratio 3.90, 95% CI 3.14-4.86) (all P values < .0001). There was no evidence of a difference in outcomes between early and late WHF (all P values for comparison ≥ .2).
CONCLUSIONS: Worsening HF during index hospitalization was associated with worse 30- and 180-day outcomes. Worsening HF may represent an important patient-centered outcome in acute HF and a focus of future treatments.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26299227      PMCID: PMC4581586          DOI: 10.1016/j.ahj.2015.04.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  19 in total

1.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.

Authors:  Barry M Massie; Christopher M O'Connor; Marco Metra; Piotr Ponikowski; John R Teerlink; Gad Cotter; Beth Davison Weatherley; John G F Cleland; Michael M Givertz; Adriaan Voors; Paul DeLucca; George A Mansoor; Christina M Salerno; Daniel M Bloomfield; Howard C Dittrich
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome.

Authors:  Guillermo Torre-Amione; Olga Milo-Cotter; Edo Kaluski; Loic Perchenet; Isaac Kobrin; Aline Frey; Michele M Rund; Beth Davison Weatherley; Gad Cotter
Journal:  J Card Fail       Date:  2009-06-13       Impact factor: 5.712

3.  Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial.

Authors:  Gregory Giamouzis; Javed Butler; Randall C Starling; George Karayannis; John Nastas; Charalambos Parisis; Dimitrios Rovithis; Dimitrios Economou; Konstantinos Savvatis; Themistoklis Kirlidis; Themistoklis Tsaknakis; John Skoularigis; Dirk Westermann; Carsten Tschöpe; Filippos Triposkiadis
Journal:  J Card Fail       Date:  2010-12       Impact factor: 5.712

4.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Authors:  Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

5.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Authors:  John J V McMurray; John R Teerlink; Gadi Cotter; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

6.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Authors:  Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

7.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.

Authors:  Gad Cotter; Howard C Dittrich; Beth Davison Weatherley; Daniel M Bloomfield; Christopher M O'Connor; Marco Metra; Barry M Massie
Journal:  J Card Fail       Date:  2008-09-14       Impact factor: 5.712

8.  Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.

Authors:  Gad Cotter; Marco Metra; Beth Davison Weatherley; Howard C Dittrich; Barry M Massie; Piotr Ponikowski; Daniel M Bloomfield; Christopher M O'Connor
Journal:  Cardiology       Date:  2009-10-20       Impact factor: 1.869

9.  Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?

Authors:  Beth Davison Weatherley; Olga Milo-Cotter; G Michael Felker; Nir Uriel; Edo Kaluski; Zvi Vered; Christopher M O'Connor; Kirkwood F Adams; Gad Cotter
Journal:  Fundam Clin Pharmacol       Date:  2009-07-28       Impact factor: 2.748

10.  Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

Authors:  Christopher M O'Connor; William T Abraham; Nancy M Albert; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Clyde W Yancy; James B Young; Gregg C Fonarow
Journal:  Am Heart J       Date:  2008-10       Impact factor: 4.749

View more
  12 in total

1.  Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Authors:  Marat Fudim; Christopher M O'Connor; Allison Dunning; Andrew P Ambrosy; Paul W Armstrong; Adrian Coles; Justin A Ezekowitz; Stephen J Greene; Marco Metra; Randall C Starling; Adriaan A Voors; Adrian F Hernandez; G Michael Felker; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2017-10-29       Impact factor: 15.534

Review 2.  The Impact of Worsening Heart Failure in the United States.

Authors:  Lauren B Cooper; Adam D DeVore; G Michael Felker
Journal:  Heart Fail Clin       Date:  2015-08-11       Impact factor: 3.179

3.  Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.

Authors:  Lauren B Cooper; Bradley G Hammill; Puza P Sharma; Adam D DeVore; Robert J Mentz; Gregg C Fonarow; Peter S Pang; Lesley H Curtis; Adrian F Hernandez
Journal:  Am Heart J       Date:  2015-09-11       Impact factor: 4.749

4.  Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.

Authors:  Jacob P Kelly; Lauren B Cooper; Dianne Gallup; Kevin J Anstrom; Horng H Chen; Margaret M Redfield; Christopher M O'Connor; Robert J Mentz; Adrian F Hernanadez; G Michael Felker
Journal:  Circ Heart Fail       Date:  2016-08       Impact factor: 8.790

5.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 6.  Interventional procedures and future drug therapy for hypertension.

Authors:  Melvin D Lobo; Paul A Sobotka; Atul Pathak
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

7.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534

Review 8.  Acute Heart Failure: Definition, Classification and Epidemiology.

Authors:  Sameer Kurmani; Iain Squire
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 9.  Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.

Authors:  Chunbin Wang; Bo Xiong; Lin Cai
Journal:  BMC Cardiovasc Disord       Date:  2017-06-20       Impact factor: 2.298

Review 10.  In-hospital worsening heart failure: a clinically relevant endpoint?

Authors:  Andrew L Clark; Myriam Cherif; Theresa A McDonagh; Iain B Squire
Journal:  ESC Heart Fail       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.